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Stromal cell-derived factor 1 (SDF-1) inhibits T-cell tropic (T-tropic) HIV-1 infection in vitro. In this study, we examined the
regulatory role of SDF-1 on HIV-1 replication in peripheral blood mononuclear cells (PBMC) of HIV-infected individuals. We
found that the amount of SDF-1 mRNA in freshly isolated PBMC of HIV-1 carriers was higher than in healthy donors.
Moreover, PBMC from some asymptomatic carriers (ACs) exhibited high levels of SDF-1 mRNA expression. The level of
SDF-1 expression in PBMC did not correlate with the magnitude of CD81 T cell-mediated suppression of HIV-1 among ACs.
SDF-1 inhibited HIV-1 replication at the viral entry step, whereas a single-cycle HIV-1 infection system showed that the major
part of the CD81 T-cell-mediated suppression occurs after intracellular penetration of the virus. Our results suggest that
SDF-1 acts as a suppressor of virus replication in a CD81 T-cell-independent mechanism in HIV-infected individuals. © 1998
Academic Press
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1), the
causative agent of acquired immunodeficiency syn-
drome (AIDS), causes a slow and progressive destruc-
tion of the immune systems and a long asymptomatic
latent period extending over 10–15 years (Fauci, 1993).
The mechanisms involved in the long asymptomatic la-
tent period are not fully understood, but probably include
host immune responses against the virus, such as cyto-
toxic T lymphocytes (CTLs), neutralizing antibodies, and
antibody-dependent cellular cytotoxicity (Weiss et al.,
1986; Ljunggren et al., 1987; Ojo-Amaize et al., 1987;
Walker et al., 1987).
In addition to these antiviral responses, a number of
studies have shown that CD81 T cells from HIV-infected
individuals are capable of suppressing viral replication in
a noncytolytic, MHC-nonrestricted manner (Walker et al.,
1986; Levy et al., 1996). This CD81 T-cell-mediated sup-
pression is effective against multiple laboratory HIV-1
strains, indicating that CD81 T cells of asymptomatic
carriers (ACs) may suppress HIV-1 replication regardless
of the dominant HIV-1 strain in vivo (Kannagi et al., 1990).
A similar CD81 T-cell-mediated suppression of viral rep-
lication has also been detected in SIV-infected ma-
caques and HIV-1-infected chimpanzees (Kannagi et al.,
1988; Castro et al., 1991).
Two host cell molecules are required for HIV-1 entry
into the cells: the first is CD4, while the other is a
member of chemokine receptors (Sattentau and Weiss,
1988; Feng et al., 1996). CD4 mediates the binding of the
virus to cells, and chemokine receptors are thought to be
involved in the virus entry process into cells. Two types
of viruses have been identified based on the host in-
fected cells (cell tropism), such as macrophage-tropic
(M-tropic) virus and T-cell-tropic (T-tropic) virus. Cell tro-
pism is determined by the chemokine receptor used by
the respective virus. Chemokine receptor CC-CKR5 and
fusin/CXCR4 act as entry cofactors for M-tropic virus
(Al-Khatib et al., 1996; Bleul et al., 1996a; Deng et al.,
1996; Dragic et al., 1996) and T-tropic virus (Feng et al.,
1996), respectively. Consistent with the chemokine re-
ceptor usage, the ligands of CC-CKR5, such as MIP1a,
MIP1b, and RANTES, inhibit infection of cells by M-tropic
HIV-1 (Cocchi et al., 1995; Oberlin et al., 1996). Similarly,
SDF-1 inhibits infection by T-tropic virus through fusin/
CXCR4 (Feng et al., 1996).
SDF-1 was initially identified as a bone-marrow stro-
mal cell-derived factor (Tashiro et al., 1993), and as a
pre-B-cell stimulatory factor (Nagasawa et al., 1994).
SDF-1 is also known as highly efficient lymphocyte che-
moattractant (Bleul et al., 1996b). Although SDF-1 blocks
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the entry of T-tropic HIV-1 to cells in vitro (Bleul et al.,
1996a; Oberlin et al., 1996), it remains to be determined
whether SDF-1 is expressed in peripheral blood mono-
nuclear cells (PBMC) of HIV-infected individuals and
whether it actually plays a role as a suppressor of HIV-1
replication in vivo.
In this study, we show a high expression of SDF-1 in
freshly isolated PBMC from HIV-1 carriers, especially
in ACs. Our results also suggest that SDF-1 is not
involved in the suppressive effect of CD81 T cells,
which is the major mechanism of suppression of HIV-1
replication in ACs.
RESULTS
Enhanced expression of SDF-1 mRNA in unstimulated
PBMC of asymptomatic carriers
Using the RT-PCR method, we measured the expres-
sion of SDF-1 mRNA in PBMC from HIV-infected individ-
uals with different stages of the disease. As shown in
Fig. 1, SDF-1 mRNA was not detected in PBMC of sero-
negative individuals (SNs). In contrast, SDF-1 mRNA ex-
pression was detected in PBMC of ACs and AIDS pa-
tients. Among the HIV-1 carriers tested, two ACs showed
markedly high levels of SDF-1 expression. These results
suggest that SDF-1 might act as an inhibitor of HIV-1
replication in carriers, particularly ACs.
Lack of correlation between SDF-1 mRNA expression
in PBMC and inhibitory effects of HIV-1 replication
Exogenous HIV-1 replicate efficiently in phytohemag-
glutinin (PHA)-activated PBMC obtained from most SNs,
whereas both endogenous and exogenous HIV-1 poorly
replicate in PBMC of ACs. The latter inhibition of HIV-1
replication is mediated by CD81 T cells (Kannagi et al.,
1990). We next assessed HIV-1 suppressive activities of
PBMC from ACs by examining the correlation with SDF-1
mRNA levels. In this assay, we used MHC-I mismatched
CD41 and CD81 T cells to exclude CTL activity which
may suppress HIV-1 replication. Consistent with previ-
ous reports, CD81 T cells from ACs exhibited significant
levels of HIV-1 inhibitory activity (average suppression:
81.4%) compared with those from SNs (average suppres-
sion: 7.1%, Fig. 2A). The CD81 T cells from a represen-
tative AC inhibited HIV-1 replication more effectively in
autologous than in allogenic CD41 T cells (Fig. 2B). In
addition, CD81 T cells from a representative SN showed
minimal levels of inhibition against both autologous and
allogenic CD41 T cells, suggesting that the anti-virus
activity of CD81 T cells in ACs was not due to allogenic
stimulation.
Since all HIV-1 replication assays were carried out
with PHA-activated PBMC, we next examined the ex-
pression of SDF-1 mRNA in PHA-stimulated PBMC to-
gether with the CD81 T-cell-mediated inhibitory activity
of HIV-1 replication. As shown in Figs. 3A and 3B, all four
PBMC samples from SNs expressed SDF-1 mRNA 7
days after the addition of PHA, and the level of expres-
sion was equivalent or more than that of ACs. However,
CD81 T cells from only one of four SNs showed a
significant inhibition of HIV-1 p24 production in CD41 T
cells (Fig. 3C). In addition, case 2 of SNs had the highest
level of SDF-1 expression among 8 cases tested, but had
no inhibitory activity against HIV-1 production. On the
other hand, p24 production by CD41 T cells was inhib-
ited to 25% in all four ACs. In case 4 of the same group,
we observed a significant level of HIV-1 inhibition with
the lowest levels of SDF-1 mRNA expression. Thus,
these results indicate that the expression level of SDF-1
mRNA does not correlate with HIV-1 suppressive activi-
ties in these HIV-infected individuals in vitro.
CD81 T cells from ACs block HIV-1 replication after
virus entry
To examine the inhibitory mechanism of CD81 T cells,
we used pseudotype HIV-1 carrying a luciferase gene.
NLlucDBgl is a derivative of NL-4-3, an infectious molec-
ular clone of T-tropic HIV-1, and has a partial deletion of
the envelope and nef genes, but instead has the lucif-
erase gene. NLlucDBgl was cotransfected into 293T
cells together with an expression plasmid of the HIV-1
envelope gene derived from NL-4-3. The pseudotype
virus (NLluc/LET) in a supernatant of 293T cells can
FIG. 1. SDF-1 mRNA expression in freshly isolated peripheral blood
mononuclear cells (PBMC). Total RNA was prepared from PBMC
freshly isolated from three seronegative subjects (SN), six asymptom-
atic carriers (AC), and three patients with AIDS. The expression of
SDF-1 mRNA in each sample was measured semiquantitatively by
RT-PCR analysis. The amount of PCR-amplified fragments separated by
polyacrylamide gel was analyzed by a sequencer. (A) The visualized
image of amplified fragments of SDF-1 and b-actin genes detected by
a sequencer. (B) SDF-1/b-actin ratio representing the amplified SDF-1
fragment relative to that of b-actin.
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infect only cells in a single cycle. In addition, replication
of this pseudotype virus can be monitored by measuring
the luciferase activity. CD41 T cells from SN were in-
fected with this pseudotype virus and then cultured with
or without CD81 T cells from AC. We detected 4000
counts per second (CPS) of luciferase activity in CD41 T
cells without CD81 T cells. However, the activity was
reduced to 400 CPS following the addition of CD81 T
cells prior to viral infection (90% suppression; Fig.4A,
lane 3). Slightly decreased but still compatible levels of
inhibition (70% suppression ) of luciferase activity were
also observed when CD81 T cells were mixed with
CD41 T cells after viral infection (Fig. 4A, lane 2). These
data indicate that CD81 T cells from ACs can effectively
inhibit HIV-1 replication even after the virus binds to
susceptible cells. We next used NLluc recombinant virus
with a heterologous envelope protein of amphotropic
MuLV. This pseudotype virus can infect cells indepen-
dent of CD4 and chemokine receptors. As shown in Fig.
4B, CD81 T cells from AC inhibited the replication of this
pseudotype virus by 80%. These results indicated that
the inhibition of HIV-1 replication by CD81 T cells mainly
occurs at the postbinding steps of the HIV-1 life cycle.
DISCUSSION
The major findings of the present study were the
enhanced expression of SDF-1 mRNA in fresh PBMC
isolated from HIV-infected individuals and the high levels
of SDF-1 mRNA expression in some asymptomatic car-
riers relative to those in patients with AIDS. Since the
expansion of T-tropic HIV-1 is associated with a rapid
decline of CD41 T cells and progression of the disease
(Tersmette et al., 1989), the high levels of SDF-1 in ACs
may contribute to the suppression of T-tropic HIV-1 rep-
lication. However, it is still not clear whether the levels of
SDF-1 mRNA can be equated to the levels of protein and
protein activity or whether the enhanced expression of
SDF-1 detected in the present study is sufficient for HIV-1
suppression in vivo. Further studies are required to clar-
ify these questions.
M-tropic HIV-1 plays an important role in primary HIV-1
infection. The expression of MIP1a, MIP1b, and RANTES
(inhibitors of replication of the M-tropic virus) is upregu-
lated in HIV-1 infected individuals, but there is no signif-
icant difference in expression between nonprogressor
and AIDS (McKenzie et al., 1996). Thus, further analysis is
also required for the defensive role of these CC chemo-
kines against the onset of the disease in vivo.
Our results showed that treatment with PHA induced
the expression of SDF-1 in PBMC of SNs (Fig. 3). Re-
cently, we also showed that the expression of SDF-1
mRNA is upregulated in T cells infected with human
T-cell leukemia virus type I (HTLV-I) and that HTLV-I
transcriptional activator Tax, which mimics activation sig-
nal in T cells, is responsible for the upregulation (Arai et
al., 1998). In addition, PBMC isolated from some patients
with active autoimmune diseases also had elevated
SDF-1 mRNA levels (Arai et al., unpublished observa-
FIG. 2. HIV-1 suppressive effects of CD81 T cells derived from asymptomatic carriers (AC). (A) CD41 T cells isolated from seronegative subjects
(SN) were infected with HIV-1 LAI and cocultured with CD81 T cells of SNs or ACs. The amount of HIV-1 p24 in the culture supernatant 4 days after
in vitro HIV-1 infection was indicated as percentage suppression as described under Materials and Methods. Horizontal bars indicate the mean
values of percentage suppression. The CD81 cells used in this experiment were isolated from randomly selected donors. (B) CD81 T cells from a
representative AC and SN were cocultured with autologous (Auto) or allogenic (Allo) CD41 T cells exogenously infected with HIV-1 LAI. The amount
of HIV-1 p24 in the culture supernatant was measured 4 days after in vitro HIV-1 infection and indicated as percentage suppression against controls
without CD81 cells.
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tions). These findings suggest that the high level of
SDF-1 expression in HIV-1 carriers is due to immune
reaction activated by viral infection.
CD81 T cells are known to secrete CC chemokines
including MIP1a, MIP1b, and RANTES (Cocchi et al.,
1995). These chemokines are at least partially responsi-
ble for CD81 T-cell-mediated suppression of M-tropic
HIV-1 but not T-tropic virus. Another major finding of the
present study was that SDF-1 is not involved in CD81
T-cell-mediated anti-HIV activity (Fig. 3). This is in agree-
ment with the recent report of Lacey et al. (1997) indicat-
ing that SDF-1 is not responsible for CD81 T cell sup-
pression and that CD81 T cells contain extremely low
levels of SDF-1.
Using a pseudotype HIV-1 carrying luciferase, we
were able to show that CD81 T cells affect HIV replica-
tion mainly after the virus binds to its receptors (Fig. 4).
These observations are compatible with previous find-
ings demonstrating that CD81 T-cell-derived antiviral ac-
tivity inhibits the HIV-1 life cycle at the transcription level
(Chen et al., 1993; Powell et al., 1993). It should be noted
that a slightly stronger inhibition against HIV-1 replica-
tion was detected when CD81 T cells were cocultured
with CD41 T cells before viral infection than after infec-
tion (Fig. 4A). This may indicate that CD81 T cells partly
inhibit viral replication at the viral entry step. Alterna-
tively, preculture of CD41 T cells with CD81 T cells
before viral infection may enhance the effectiveness of
inhibition at the postbinding steps of the HIV-1 life cycle.
In conclusion, expression of SDF-1 transcripts in
PBMC of HIV-1 carriers is significantly high, particularly
in ACs, which may, at least in part, contribute to the
suppression of HIV-1 in vivo. However, SDF-1 is unlikely
to be involved in CD81 T-cell-mediated suppression of
HIV-1 in PBMC of ACs.
MATERIALS AND METHODS
Isolation of peripheral blood mononuclear cells
Blood specimens were obtained from 17 HIV-1 asymp-
tomatic carriers with 200–500/ml of peripheral CD41 T
lymphocytes and from 3 AIDS patients with ,200/ml of
CD41 T cells. Control specimens were obtained from 11
healthy SNs. PBMC were isolated on a Ficoll–Paque
(Pharmacia Biotech, Uppsala, Sweden) gradient and im-
mediately used for isolation of total RNAs or stimulated
with PHA (Difco Laboratories, Detroit, MI) for 24 h. Cells
were then washed and cultured in RPMI 1640 medium
(GIBCO Laboratories, Grand Island, NY) containing 2
ng/ml of recombinant IL-2 (Shionogi, Osaka, Japan) and
10% FCS (Whittaker, Walkersville, MD) and used for ex-
periments after 7 days of PHA stimulation.
CD81 T cells were prepared by depleting CD41 cells
from cultured PBMC using a magnetic particle concen-
trator and Dynabeads M-450 (Dynal A. S., Oslo, Norway)
coated with anti-CD4 antibody. CD41 T cells were iso-
lated from PBMC by depleting CD81 cells using Dyna-
beads coated with anti-CD8 antibody.
Semiquantitative reverse transcriptase–polymerase
chain reaction analysis
RNA was extracted from PBMC according to the Iso-
gen method described previously (Chomczynski, 1993).
For reverse transcriptase–polymerase chain reaction
(RT-PCR) analysis, rTth DNA polymerase with reverse
transcriptase activity was used for reverse transcription
and sequential reaction in the presence of sense and
antisense primers (Perkin–Elmer). Primers used for the
amplification of SDF-1 and b-actin were 59-CCGCGCTCT-
GCCTCAGCGACGGGAAG-39 (sense primer), 59-CTTGTT-
TAAAGCTTTCTCCAGGTACT-39 (antisense primer) and
59-AAGAGAGGCATCCTCACCCT-39 (sense primer), 59-TA-
GATGGCTGGGGTGTTGAA-39 (antisense primer), respec-
FIG. 3. SDF-1 mRNA expression in PHA-stimulated PBMC did not
correlate with HIV-1-suppressive activity of CD81 T cells. (A) Total
RNA was prepared from PHA-stimulated PBMC of four seronegative
subjects (SN) and four asymptomatic carriers (AC) and the express
ion of SDF-1 mRNA in each sample was measured semiquantita-
tively by RT-PCR analysis. The PCR-amplified fragments separated
by a polyacrylamide gel were analyzed by a sequencer. The visual-
ized image of amplified fragments of SDF-1 and b-actin genes
detected by a sequencer are shown. (B) SDF-1/b-actin ratio repre-
senting the amplified SDF-1 fragment relative to that of b-actin. (C)
HIV-1 suppressive effects of CD81 T cells derived from the same
individuals. Experiments were carried out in a manner similar to that
described in the legend of Fig. 2A.
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tively. The sense primers for SDF-1 and b-actin were
labeled with 6-carboxyfluorescein (6-FAM) and 4, 7, 29,
79-tetrachloro-6-carboxyfluorescein (TET), respectively.
The amounts of expected 227-bp (SDF-1) and 218-bp
(b-actin) fragments were quantified by measuring their
absorbency at 532 nm (6-FAM) and at 543 nm (TET) with
a sequencer (Prism 377, Applied Biosystems) according
to the instructions provided by the manufacturer. The
relative amount of SDF-1 RNA represented the amount of
the SDF-1 fragment relative to that of b-actin after am-
plification at linear phases.
Viruses
HIV-1 LAI infectious supernatants were obtained from
infected MOLT-4/HIV-1 LAI C-3 cells (Harada et al., 1987).
Luciferase-expressing viruses capable of a single repli-
cation cycle were generated by cotransfection of 293T
cells with pNLlucDBgl encoding env-defective NL-4-3
HIV-1 sequences (Planelles et al., 1995) and pLET en-
coding the env gene of HIV LAI (NLluc/LET) (Langlade-
Demoyen et al., 1988) by using the calcium phosphate
method. Amphotropic MuLV envelope-expressing pJD-1
(NLluc/JD-1) was also used (Dougherty et al., 1989).
These plasmids were kindly provided by Dr. Irvin S. Y.
Chen, from the University of California at Los Angeles.
Culture supernatants were collected after 48 h of trans-
fection and used immediately for infection.
In vitro HIV-1 infection of PBMC
CD41 T cells separated from PBMC as described
above were incubated with culture supernatants contain-
ing HIV-1 LAI (MOI 0.1–0.01), NLluc/LET, or NLluc/JD-1 at
37°C for 3 h and washed extensively. The virus-infected
CD41 T cells (1 3 105) were cocultured with CD81 T
cells (1 3 105) in a round-bottom 96-well plate for 4 days
for p24 assay or for 2 days for luciferase assay. In some
experiments, CD41 and CD81 T cells were cocultured
for 2 days, then infected with NLluc/LET, and assayed for
luciferase activity after 2 days of infection.
Quantitation of HIV-1 p24
HIV-1 p24 antigen in the culture supernatants was
measured with an enzyme immunoassay system, EIA-II
(Abbott Diagnostika, Wiesbaden-Delkenheim, Germany),
according to the instructions provided by the manufac-
turer. Percentage suppression was calculated using the
formula [(1 2 test p24 value /medium control p24 value)
3 100].
Luciferase assay
After two days of infection, 100 ml of cell suspension
was lysed with 25 ml of 53 luciferase lysis buffer (Pro-
mega). A 20-ml section of each lysate was assayed for
photon emission with a luminometer (LUMAT; EG&G
Berthold, Bad Wildbad, Germany) by using the Promega
Luciferase Assay System. Luciferase activity was indi-
cated as counts per second.
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